Memórias do Instituto Oswaldo Cruz · 2009 · 13 citations · 17 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceMolecular VirologyVirologyAntiretroviral TherapyAntiviral Drug ResistanceAntiviral ResistanceAntiviral TherapyHiv EpidemiologyResistance EpidemiologyDrug Resistance MutationsGenotypic Resistance ProfilingGenotypic Resistance TestingHiv Drug Resistance EpidemiologyNon-nucleoside AntiviralsNon-nucleoside InhibitorsNon-nucleoside Reverse Transcriptase InhibitorsResistance-associated Mutations
An in-house, low-cost method was developed to determine the genotypic resistance of immunodeficiency virus type 1 (HIV-1) isolates. All 179 Venezuelan isolates analysed belonged to subtype B. Primary drug resistance mutations were found in 11% of 63 treatment-naïve patients. The prevalence of resistance in isolates from 116 HIV-positive patients under antiretroviral treatment was 47% to protease inhibitors, 65% to nucleoside inhibitors and 38% to non-nucleoside inhibitors, respectively. Around 50% of patients in the study harboured viruses with highly reduced susceptibility to the three classical types of drugs after only five years from their initial diagnoses.
17
The prevalence of antiretroviral drug resistance in the United States
Douglas D. Richman, Sally C. Morton, Terri Wrin et al. · AIDS · 2004 · 412 citations
Update of the drug resistance mutations in HIV-1: Fall 2005.
Victoria A. Johnson, Françoise Brun‐Vézinet, Bonaventura Clotet et al. · PubMed · 2006 · 263 citations
Update of the drug resistance mutations in HIV-1: Fall 2006.
Victoria A. Johnson, Françoise Brun‐Vézinet, Bonaventura Clotet et al. · PubMed · 2006 · 172 citations
José Carlos Couto-Fernandez, Milene Alvarenga Rachid, RSG Gracie et al. · Memórias do Instituto Oswaldo Cruz · 2005 · 71 citations · Full text